Skip to main content

Um in den USA zu traden, geh zu polymarket.us

icon for Heidi Overton als FDA-Kommissarin bestätigt von...?
Politik·Trump

Heidi Overton als FDA-Kommissarin bestätigt von...?

icon for Heidi Overton als FDA-Kommissarin bestätigt von...?
Politik·Trump

Heidi Overton als FDA-Kommissarin bestätigt von...?

$19,662 Vol.

30. Sep. 2026
Polymarket

$19,662 Vol.

Polymarket

30. September

$11,104 Vol.

7%

31. Oktober

$4,762 Vol.

37%

30. November

$1,097 Vol.

31%

31. Dezember

$2,700 Vol.

59%

This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”. If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”. The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution. The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by October 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”. If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”. The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution. The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by November 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”. If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”. The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution. The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”. If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”. The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution. The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.President Trump's August 2026 nomination of White House domestic policy aide Heidi Overton, a physician with prior roles at the America First Policy Institute, to lead the FDA follows the May resignation of commissioner Marty Makary amid agency turnover and policy clashes. Confirmation requires Senate approval, beginning with the Health, Education, Labor and Pensions Committee. Chair Bill Cassidy has voiced strong concerns about Overton's limited managerial experience and her involvement in recent executive actions on childhood vaccines, signaling potential delays or obstacles in a narrowly Republican-led chamber. Democrats have also raised objections. The FDA continues to manage staffing reductions, morale issues, and ongoing regulatory priorities under acting leadership, with traders monitoring hearing timelines and vote counts for signals on confirmation prospects.

This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.

If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.

The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.

The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”. If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”. The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution. The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.
Volumen
$19,662
Enddatum
1. Jan. 2027
Markt eröffnet
Aug 20, 2026, 5:43 PM ET

Abwickler

0x65070BE91...
This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”. If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”. The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution. The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by October 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”. If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”. The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution. The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by November 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”. If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”. The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution. The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”. If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”. The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution. The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.President Trump's August 2026 nomination of White House domestic policy aide Heidi Overton, a physician with prior roles at the America First Policy Institute, to lead the FDA follows the May resignation of commissioner Marty Makary amid agency turnover and policy clashes. Confirmation requires Senate approval, beginning with the Health, Education, Labor and Pensions Committee. Chair Bill Cassidy has voiced strong concerns about Overton's limited managerial experience and her involvement in recent executive actions on childhood vaccines, signaling potential delays or obstacles in a narrowly Republican-led chamber. Democrats have also raised objections. The FDA continues to manage staffing reductions, morale issues, and ongoing regulatory priorities under acting leadership, with traders monitoring hearing timelines and vote counts for signals on confirmation prospects.

This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.

If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.

The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.

The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”. If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”. The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution. The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.
Volumen
$19,662
Enddatum
1. Jan. 2027
Markt eröffnet
Aug 20, 2026, 5:43 PM ET

Abwickler

0x65070BE91...

Verwandte

icon for Wird Hung Cao bis zum 31. Dezember als Marineminister bestätigt werden?

Wird Hung Cao bis zum 31. Dezember als Marineminister bestätigt werden?

56%
Ja
icon for Wird der Kongress im Jahr 2026 ein Veto überstimmen?

Wird der Kongress im Jahr 2026 ein Veto überstimmen?

5%
Ja
icon for Howard Lutnick out as Secretary of Commerce by December 31?

Howard Lutnick out as Secretary of Commerce by December 31?

20%

Vorsicht bei externen Links.

Häufig gestellte Fragen

„Heidi Overton als FDA-Kommissarin bestätigt von...?" ist ein Prognosemarkt auf Polymarket mit 4 möglichen Ergebnissen, bei dem Händler Anteile auf Basis ihrer Einschätzung kaufen und verkaufen. Das aktuell führende Ergebnis ist „31. Dezember" mit 59%, gefolgt von „31. Oktober" mit 37%. Die Preise spiegeln Echtzeit-Wahrscheinlichkeiten der Community wider. Ein Anteilspreis von 59¢ bedeutet, dass der Markt diesem Ergebnis eine Wahrscheinlichkeit von 59% zuweist. Diese Quoten ändern sich laufend, wenn Händler auf neue Entwicklungen reagieren. Anteile am richtigen Ergebnis können bei Marktauflösung für jeweils $1 eingelöst werden.

Stand heute hat „Heidi Overton als FDA-Kommissarin bestätigt von...?" ein Gesamthandelsvolumen von $19.7K generiert, seit der Markt am Aug 20, 2026 gestartet wurde. Dieses Aktivitätsniveau spiegelt starkes Engagement der Polymarket-Community wider und stellt sicher, dass die aktuellen Quoten von einem breiten Pool an Marktteilnehmern geprägt werden. Sie können Live-Preisbewegungen verfolgen und direkt auf dieser Seite auf jedes Ergebnis handeln.

Um auf „Heidi Overton als FDA-Kommissarin bestätigt von...?" zu handeln, durchsuchen Sie die 4 verfügbaren Ergebnisse auf dieser Seite. Jedes Ergebnis zeigt einen aktuellen Preis, der die implizierte Wahrscheinlichkeit des Marktes darstellt. Um eine Position einzunehmen, wählen Sie das Ergebnis, das Sie für am wahrscheinlichsten halten, wählen Sie „Ja" um dafür oder „Nein" um dagegen zu handeln, geben Sie Ihren Betrag ein und klicken Sie auf „Handeln". Liegt Ihr gewähltes Ergebnis bei Marktauflösung richtig, zahlen Ihre „Ja"-Anteile jeweils $1 aus. Liegt es falsch, zahlen sie $0. Sie können Ihre Anteile auch jederzeit vor der Auflösung verkaufen.

Der aktuelle Favorit für „Heidi Overton als FDA-Kommissarin bestätigt von...?" ist „31. Dezember" mit 59%, was bedeutet, dass der Markt diesem Ergebnis eine Wahrscheinlichkeit von 59% zuweist. Das nächstliegende Ergebnis ist „31. Oktober" mit 37%. Diese Quoten werden in Echtzeit aktualisiert, wenn Händler Anteile kaufen und verkaufen. Schauen Sie regelmäßig vorbei oder speichern Sie diese Seite als Lesezeichen.

Die Auflösungsregeln für „Heidi Overton als FDA-Kommissarin bestätigt von...?" definieren genau, was passieren muss, damit jedes Ergebnis als Gewinner erklärt wird – einschließlich der offiziellen Datenquellen zur Bestimmung des Ergebnisses. Sie können die vollständigen Auflösungskriterien im Abschnitt „Regeln" auf dieser Seite über den Kommentaren einsehen. Wir empfehlen, die Regeln vor dem Handeln sorgfältig zu lesen, da sie die genauen Bedingungen, Sonderfälle und Quellen festlegen.